Lung Cancer

Researchers report that an analysis of ALK copy number in circulating tumor cells before starting crizotinib treatment and after 2 months of crizotinib treatment may provide a biomarker for predicting the effectiveness of the drug.

The FDA has approved brigatinib (Alunbrig) for the treatment of metastatic ALK-positive non-small-cell lung cancer, specifically in patients who have progressed on or are intolerant to crizotinib.

Peripheral blood analysis may provide valuable insights into non–small-cell lung cancer patients’ responses to PD-1-targeted therapies.

Circulating tumor DNA blood tests can rapidly identify treatment-targetable tumor mutations in patients diagnosed with non–small-cell lung cancer.

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy regimens failed to prolong overall survival in lung and breast cancers.

Dr. Heather Wakelee discusses the management of lung cancer patients who have early or delayed progression while being treated with an immune checkpoint inhibitor.

We spoke with Dr. Gerald Falchook about the first human study of a first-in-class molecule, fatty acid synthase inhibitor known as TVB-2640 for advanced solid tumors.

We spoke with Dr. Julie Brahmer about how survival rates are starting to improve with the use of nivolumab in non-small cell lung cancer.

In this video we discuss a new study that tested the feasibility of using circulating tumor cells to detect recurrence in patients with locally advanced non–small-cell lung cancer.

This video discusses possible methods to help reduce racial disparities in the treatment and outcomes of early-stage lung cancer.

This video examines racial disparities in treatment and survival outcomes among stage I non–small-cell lung cancer lung cancer patients.

The FDA on March 30, 2017, granted full approval to osimertinib for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC.

This video discusses the phase I trial of rovalpituzumab (Rova-T) for the treatment of patients with small-cell lung cancer.

Quantitative morphological features of tumor pathological images may help predict prognosis in patients with non-small cell lung cancer.

A study of the combination of radiation therapy and immune checkpoint inhibitors for the treatment of advanced lung cancer found a modest risk of side effects.

This video highlights some of the latest developments guiding precision medicine for lung cancer in clinical practice.

In this interview we discuss how quality-of-life information from patients with lung cancer can be used to help guide treatment and inform outcomes.

The use of reirradiation with intensity-modulated proton therapy yielded strong overall survival with limited toxicity in patients with thoracic tumors, potentially offering a new option in this patient population.

This video examines updated data from a phase II trial that compared a single dose of high-intensity SBRT with a standard three-dose schedule as treatment for patients with non-small-cell lung cancer.

This video examines the safety and efficacy of definitive stereotactic body radiation therapy in patients 80 and older with inoperable, early-stage lung cancer.

This video examines the results of a retrospective study that compared chemotherapy alone or with prophylactic cranial irradiation in extensive-stage SCLC patients with no brain metastases.

The use of a customized clinical pathways program that helps manage complexity and guide decisions resulted in a sharp decrease in costs per patient in an analysis of stage IV non–small-cell lung cancer.

ERBB2/HER2 mutations appear to be rare but targetable oncogenic drivers in non-small cell lung cancer, according to findings from a small retrospective cohort records analysis.

The LUX-Lung 7 trial found no significant differences between afatinib and gefitinib for patients with EGFR mutation–positive stage IIIb/IV NSCLC.

An IHC assay for ALK status in non-small cell lung cancer tumor tissue predicts crizotinib treatment outcomes and offers a rapid and potentially less expensive alternative to older FISH ALK status assays.